Prevalence and Clinical Characteristics of Obsessive-Compulsive Symptoms Associated With Atypical Antipsychotics

Lim, Meerae; Park, Dong Yeon; Kwon, Jun Soo; Joo, Yeon Ho; Hong, Kyung Sue

doi:10.1097/jcp.0b013e31815a584c

Cited by 43 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous investigation, we screened 209 clinically stable outpatients with schizophrenia who were receiving AAP and found that 12.4% showed AAP-induced OC symptoms. 10 It is widely accepted that genetic factors play an important role in an individual's susceptibility to various AAP adverse effects, 11,12 and this assumption is the theoretical basis of pharmacogenetic studies. Nonetheless, heritability data for antipsychotic drug responses are extremely limited because of difficulties recruiting twin pairs who have received the same AAP treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Genotype and haplotype frequencies were investigated in the OC and non-OC groups for 10 single-nucleotide polymorphisms (SNPs) in the 3Ј region of SLC1A1 including SNPs that showed significant association with OCD in previous studies. [22][23][24] As AAP-induced OC symptoms are most frequently observed in clozapine-treated patients, 1,8,10 we performed a subgroup analysis for clozapine-induced OC symptoms. To the best of our knowledge, this is the first pharmacogenetic study investigating AAP-induced OC symptoms.…”

Section: Arch Genmentioning

confidence: 99%

“…Therefore, we included patients who had been receiving AAP for more than 24 months without development of any OC symptoms in the non-OC group. Because AAP-induced OC symptoms showed preponderance in men and were most frequently observed in clozapine-treated patients, 1,8,10 we tried to match sex and type of AAP between the OC and non-OC groups. We also controlled for these variables in the logistic regression model used in the analysis.…”

Section: Commentmentioning

confidence: 99%

See 2 more Smart Citations

Association of the Glutamate Transporter Gene SLC1A1 With Atypical Antipsychotics–Induced Obsessive-compulsive Symptoms

Kwon¹,

Joo²,

Nam³

et al. 2009

Arch Gen Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Arch Genmentioning

confidence: 99%

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

Association of the Glutamate Transporter Gene SLC1A1 With Atypical Antipsychotics–Induced Obsessive-compulsive Symptoms

Kwon¹,

Joo²,

Nam³

et al. 2009

Arch Gen Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…estimated that up to 70% of schizophrenics treated with antiserotonergic SGAs such as CLZ, olanzapine or risperidone develop secondary OCS [1]. Independent studies report equally high numbers of SGA-induced OCS within samples of comorbid patients: 25 of 28 [62], 29 of 39 [63] and 23 of 26 [64]. …”

Section: Epidemiologymentioning

confidence: 99%

Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review

Schirmbeck¹,

Zink

2012

113

104

View full text Add to dashboard Cite

Obsessive-compulsive disorder (OCD) is rarely associated with schizophrenia, whereas 20 to 30% of schizophrenic patients, suffer from comorbid obsessive-compulsive symptoms (OCS). So far no single pathogenetic theory convincingly explained this fact suggesting heterogeneous subgroups. Based on long-term case observations, one hypothesis assumes that second-onset OCS in the course of schizophrenia might be a side effect of second generation antipsychotics (SGA), most importantly clozapine (CLZ). This review summarizes the supporting epidemiological and pharmacological evidence: Estimations on prevalence of OCS increase in more recent cross-sectional studies and in later disease stages. Longitudinal observations report the de novo-onset of OCS under clozapine treatment. This association has not been reported with first generation antipsychotics (FGA) or SGAs with mainly dopaminergic mode of action. Finally, significant correlations of OCS-severity with duration of treatment, dose and serum levels suggest clozapine-induced OCS. However, supposed causal interactions need further verifications. It is also unclear, which neurobiological mechanisms might underlie the pathogenetic process. Detailed genotypic and phenotypic characterizations of schizophrenics with comorbid OCS regarding neurocognitive functioning and activation in sensitive tasks of functional magnetic imaging are needed. Multimodal large-scaled prospective studies are necessary to define patients at risk for second-onset OCS and to improve early detection and therapeutic interventions.

show abstract

“…This study provides a new insight in this area. Subtype analyses of previous studies suggested that clozapine treatment can induce de-novo onset of OCS at a rate of 20-28% (Lin et al, 2006;Ertugrul et al, 2005;Lim et al, 2007). These findings also suggest that clozapine can induce full threshold OCD, although less frequently.…”

Section: Discussionmentioning

confidence: 49%

Suicidality in clozapine-treated patients with schizophrenia: Role of obsessive-compulsive symptoms

Szmulewicz¹,

Smith²,

Valerio³

2015

Psychiatry Research

View full text Add to dashboard Cite

Prevalence and Clinical Characteristics of Obsessive-Compulsive Symptoms Associated With Atypical Antipsychotics

Cited by 43 publications

References 9 publications

Association of the Glutamate Transporter Gene SLC1A1 With Atypical Antipsychotics–Induced Obsessive-compulsive Symptoms

Association of the Glutamate Transporter Gene SLC1A1 With Atypical Antipsychotics–Induced Obsessive-compulsive Symptoms

Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review

Suicidality in clozapine-treated patients with schizophrenia: Role of obsessive-compulsive symptoms

Contact Info

Product

Resources

About